PDF(Pubmed)
Abstract：
Preimplantation genetic testing for aneuploidy (PGT-A) is an emerging technology that aims to identify euploid embryos for transfer, reducing the risk of embryonic chromosomal abnormalities. However, the clinical benefits of PGT-A in recurrent pregnancy failure (RPF) patients, particularly in young RPF patients, remains uncertain.
This meta-analysis aimed to determine whether RPF patients undergoing PGT-A had better clinical outcomes compared to those not undergoing PGT-A, thus assessing the value of PGT-A in clinical practice.
We systematically searched PubMed, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP Database for Chinese Technical Periodicals (VIP) from 2002 to 2022. Thirteen published studies involving 930 RPF patients screened using PGT-A and over 1,434 RPF patients screened without PGT-A were included in this meta-analysis. Clinical outcomes were evaluated based on embryo transfers after PGT-A (n=1,015) and without PGT-A (n=1,799).
The PGT-A group demonstrated superior clinical outcomes compared to the in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) group. The PGT-A group had a significantly higher implantation rate (IR) (RR=2.01, 95% CI: [1.73; 2.34]), clinical pregnancy rate (CPR) (RR=1.53, 95% CI: [1.36; 1.71]), ongoing pregnancy rate (OPR) (RR=1.76, 95% CI: [1.35; 2.29]), live birth rate (LBR) (RR=1.75, 95% CI: [1.51; 2.03]), and significantly lower clinical miscarriage rate (CMR) (RR=0.74, 95% CI: [0.54; 0.99]). Subgroup analysis based on patient age (under 35 years and 35 years or older) showed that both PGT-A subgroups had significantly better CPR (P<0.01) and LBR (P<0.05) values compared to the IVF/ICSI groups.
This meta-analysis demonstrates that PGT-A in RPF patients, is associated with improved clinical outcomes, including higher IR, CPR, OPR, and LBR values, and lower CMR compared to the IVF/ICSI group. These findings support the positive clinical application of PGT-A in RPF patients.
http://INPLASY.com, identifier INPLASY 202320118.
This meta-analysis aimed to determine whether RPF patients undergoing PGT-A had better clinical outcomes compared to those not undergoing PGT-A, thus assessing the value of PGT-A in clinical practice.
We systematically searched PubMed, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP Database for Chinese Technical Periodicals (VIP) from 2002 to 2022. Thirteen published studies involving 930 RPF patients screened using PGT-A and over 1,434 RPF patients screened without PGT-A were included in this meta-analysis. Clinical outcomes were evaluated based on embryo transfers after PGT-A (n=1,015) and without PGT-A (n=1,799).
The PGT-A group demonstrated superior clinical outcomes compared to the in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) group. The PGT-A group had a significantly higher implantation rate (IR) (RR=2.01, 95% CI: [1.73; 2.34]), clinical pregnancy rate (CPR) (RR=1.53, 95% CI: [1.36; 1.71]), ongoing pregnancy rate (OPR) (RR=1.76, 95% CI: [1.35; 2.29]), live birth rate (LBR) (RR=1.75, 95% CI: [1.51; 2.03]), and significantly lower clinical miscarriage rate (CMR) (RR=0.74, 95% CI: [0.54; 0.99]). Subgroup analysis based on patient age (under 35 years and 35 years or older) showed that both PGT-A subgroups had significantly better CPR (P<0.01) and LBR (P<0.05) values compared to the IVF/ICSI groups.
This meta-analysis demonstrates that PGT-A in RPF patients, is associated with improved clinical outcomes, including higher IR, CPR, OPR, and LBR values, and lower CMR compared to the IVF/ICSI group. These findings support the positive clinical application of PGT-A in RPF patients.
http://INPLASY.com, identifier INPLASY 202320118.
摘要：
■非整倍体的植入前遗传测试（PGT-A）是一项新兴技术，旨在鉴定用于移植的整倍体胚胎，降低胚胎染色体异常的风险。然而,PGT-A在复发性妊娠失败（RPF）患者中的临床益处，特别是在年轻的RPF患者中，仍然不确定。
■这项荟萃分析旨在确定接受PGT-A的RPF患者与未接受PGT-A的患者相比是否具有更好的临床结果，从而评估PGT-A在临床实践中的价值。
■我们系统地搜索了PubMed，Cochrane图书馆,中国国家知识基础设施(CNKI),万方数据,和2002年至2022年的中国技术期刊（VIP）VIP数据库。该荟萃分析包括13项已发表的研究，涉及使用PGT-A筛查的930名RPF患者和不使用PGT-A筛查的1,434名RPF患者。根据PGT-A（n=1,015）和不含PGT-A（n=1,799）的胚胎移植评估临床结果。
与体外受精（IVF）/卵胞浆内单精子注射（ICSI）组相比，PGT-A组表现出更好的临床结局。PGT-A组的植入率（IR）明显更高（RR=2.01，95％CI：[1.73;2.34]），临床妊娠率（CPR）（RR=1.53，95%CI：[1.36;1.71]），持续妊娠率（OPR）（RR=1.76，95%CI：[1.35;2.29]），活产率（LBR）（RR=1.75，95%CI：[1.51；2.03]），显著降低临床流产率（CMR）（RR=0.74，95%CI：[0.54;0.99]）。基于患者年龄（35岁以下和35岁或以上）的亚组分析显示，与IVF/ICSI组相比，两个PGT-A亚组的CPR（P<0.01）和LBR（P<0.05）值均明显更好。
■这项荟萃分析表明，PGT-A在RPF患者中，与改善的临床结果相关，包括更高的IR，CPR,OPR,和LBR值，与IVF/ICSI组相比，CMR较低。这些发现支持PGT-A在RPF患者中的积极临床应用。
■http://INPLASY.com,标识符INPLASY202320118。
■这项荟萃分析旨在确定接受PGT-A的RPF患者与未接受PGT-A的患者相比是否具有更好的临床结果，从而评估PGT-A在临床实践中的价值。
■我们系统地搜索了PubMed，Cochrane图书馆,中国国家知识基础设施(CNKI),万方数据,和2002年至2022年的中国技术期刊（VIP）VIP数据库。该荟萃分析包括13项已发表的研究，涉及使用PGT-A筛查的930名RPF患者和不使用PGT-A筛查的1,434名RPF患者。根据PGT-A（n=1,015）和不含PGT-A（n=1,799）的胚胎移植评估临床结果。
与体外受精（IVF）/卵胞浆内单精子注射（ICSI）组相比，PGT-A组表现出更好的临床结局。PGT-A组的植入率（IR）明显更高（RR=2.01，95％CI：[1.73;2.34]），临床妊娠率（CPR）（RR=1.53，95%CI：[1.36;1.71]），持续妊娠率（OPR）（RR=1.76，95%CI：[1.35;2.29]），活产率（LBR）（RR=1.75，95%CI：[1.51；2.03]），显著降低临床流产率（CMR）（RR=0.74，95%CI：[0.54;0.99]）。基于患者年龄（35岁以下和35岁或以上）的亚组分析显示，与IVF/ICSI组相比，两个PGT-A亚组的CPR（P<0.01）和LBR（P<0.05）值均明显更好。
■这项荟萃分析表明，PGT-A在RPF患者中，与改善的临床结果相关，包括更高的IR，CPR,OPR,和LBR值，与IVF/ICSI组相比，CMR较低。这些发现支持PGT-A在RPF患者中的积极临床应用。
■http://INPLASY.com,标识符INPLASY202320118。
